SCHEMBL2564706

SCHEMBL2564706

CCCCOc1ccc(-n2c(SCCCC(=O)NCCC#N)nc3cc[nH]c3c2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.39
USP2 O75604 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 5/20 0.39
MAPT P10636 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
FADS1 O60427 1/20 0.38
PPARG P37231 1/20 0.38
ALDH1A1 P00352 4/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 2/20 0.37
BRD4 O60885 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989209 0.95 KDM4E (0.44) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2566938 0.93 ALDH1A1 (0.43) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2566556 0.93 FADS1 (0.38) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL13266354 0.92 FADS1 (0.37) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2566922 0.92 KDM4E (0.44) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2567953 0.91 FADS1 (0.41) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2567929 0.91 FADS1 (0.41) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2564419 0.91 FADS1 (0.42) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL2563086 0.90 TP53 (0.36) RXFP1USP2CRHBPCRHR2KDM4E
SCHEMBL3003973 0.90 KDM4E (0.45) RXFP1USP2CRHBPCRHR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES RXFP1 2962/4885USP2 4669/4885CRHBP 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.